Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three different doses (275, 550 AND 1100 mg) of rifaximin [XIFAXIN] administered BID [twice-daily] for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome

Trial Profile

Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three different doses (275, 550 AND 1100 mg) of rifaximin [XIFAXIN] administered BID [twice-daily] for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 07 Oct 2008 Results presented at the American College of Gastroenterology.
    • 03 Oct 2008 Results presented at ACG 2008.
    • 20 May 2008 Top-line results reported in a Salix Pharmaceuticals media release (9090646).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top